PURPOSE: To study cerebral adenosine receptors (AR) in premanifest and manifest stages of Huntington's disease (HD). METHODS: We quantified the cerebral binding potential (BP ND) of the A₁AR in carriers of the HD CAG trinucleotide repeat expansion using the radioligand [(18) F]CPFPX and PET. Four groups were investigated: (i) premanifest individuals far (preHD-A; n = 7) or (ii) near (preHD-B; n = 6) to the predicted symptom onset, (iii) manifest HD patients (n = 8), and (iv) controls (n = 36). RESULTS: Cerebral A₁AR values of preHD-A subjects were generally higher than those of controls (by up to 31%, p < .01, in the thalamus on average). Across stages a successive reduction of A₁AR BPND was observed to the levels of controls in preHD-B and undercutting controls in manifest HD by down to 25%, p < .01, in the caudatus and amygdala. There was a strong correlation between A₁AR BP ND and years to onset. Before onset of HD, the assumed annual rates of change of A₁AR density were -1.2% in the caudatus, -1.7% in the thalamus and -3.4% in the amygdala, while the corresponding volume losses amounted to 0.6%, 0.1% and 0.2%, respectively. CONCLUSIONS: Adenosine receptors switch from supra to subnormal levels during phenoconversion of HD. This differential regulation may play a role in the pathophysiology of altered energy metabolism.
PURPOSE: To study cerebral adenosine receptors (AR) in premanifest and manifest stages of Huntington's disease (HD). METHODS: We quantified the cerebral binding potential (BP ND) of the A₁AR in carriers of the HDCAGtrinucleotide repeat expansion using the radioligand [(18) F]CPFPX and PET. Four groups were investigated: (i) premanifest individuals far (preHD-A; n = 7) or (ii) near (preHD-B; n = 6) to the predicted symptom onset, (iii) manifest HDpatients (n = 8), and (iv) controls (n = 36). RESULTS: Cerebral A₁AR values of preHD-A subjects were generally higher than those of controls (by up to 31%, p < .01, in the thalamus on average). Across stages a successive reduction of A₁AR BPND was observed to the levels of controls in preHD-B and undercutting controls in manifest HD by down to 25%, p < .01, in the caudatus and amygdala. There was a strong correlation between A₁AR BP ND and years to onset. Before onset of HD, the assumed annual rates of change of A₁AR density were -1.2% in the caudatus, -1.7% in the thalamus and -3.4% in the amygdala, while the corresponding volume losses amounted to 0.6%, 0.1% and 0.2%, respectively. CONCLUSIONS:Adenosine receptors switch from supra to subnormal levels during phenoconversion of HD. This differential regulation may play a role in the pathophysiology of altered energy metabolism.
Authors: Sarah J Tabrizi; Ralf Reilmann; Raymund A C Roos; Alexandra Durr; Blair Leavitt; Gail Owen; Rebecca Jones; Hans Johnson; David Craufurd; Stephen L Hicks; Christopher Kennard; Bernhard Landwehrmeyer; Julie C Stout; Beth Borowsky; Rachael I Scahill; Chris Frost; Douglas R Langbehn Journal: Lancet Neurol Date: 2011-12-02 Impact factor: 44.182
Authors: Marcus H Holschbach; Ray A Olsson; Dirk Bier; Walter Wutz; Wiebke Sihver; Manfred Schüller; Bettina Palm; Heinz H Coenen Journal: J Med Chem Date: 2002-11-07 Impact factor: 7.446
Authors: T C Andrews; R A Weeks; N Turjanski; R N Gunn; L H Watkins; B Sahakian; J R Hodges; A E Rosser; N W Wood; D J Brooks Journal: Brain Date: 1999-12 Impact factor: 13.501
Authors: A Feigin; C Tang; Y Ma; P Mattis; D Zgaljardic; M Guttman; J S Paulsen; V Dhawan; D Eidelberg Journal: Brain Date: 2007-09-24 Impact factor: 13.501
Authors: Peter D Alfinito; Sheng-Ping Wang; Lawrence Manzino; Sonia Rijhsinghani; Gail D Zeevalk; Patricia K Sonsalla Journal: J Neurosci Date: 2003-11-26 Impact factor: 6.167
Authors: Holger K Eltzschig; Parween Abdulla; Edgar Hoffman; Kathryn E Hamilton; Dionne Daniels; Caroline Schönfeld; Michaela Löffler; German Reyes; Michael Duszenko; Jorn Karhausen; Andreas Robinson; Karen A Westerman; Imogen R Coe; Sean P Colgan Journal: J Exp Med Date: 2005-12-05 Impact factor: 14.307
Authors: Ana Joya; María Ardaya; Alejandro Montilla; Maider Garbizu; Sandra Plaza-García; Vanessa Gómez-Vallejo; Daniel Padro; Juan José Gutiérrez; Xabier Rios; Pedro Ramos-Cabrer; Unai Cossío; Krishna R Pulagam; Makoto Higuchi; María Domercq; Fabio Cavaliere; Carlos Matute; Jordi Llop; Abraham Martín Journal: Theranostics Date: 2021-01-01 Impact factor: 11.556